Lowest Price Guaranteed From USD 4,899
Published
January 2020
Pages
508
View Count
13516
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
Stem cell therapies are viable alternatives to conventional treatments with substantial therapeutic potential; market opportunities are huge, as multiple product candidates are expected to be approved over the coming decade
-- Chief Executive Officer, a US based Small-sized Company
The global stem cell therapies market to be worth $8.5 billion by 2030, growing at an annualized rate of over 30%. According to the WHO, in 2020, nearly 75% of fatalities that are estimated to be reported across the globe, are likely to be caused due to diseases, such as chronic stroke disease, diabetes, cancer, heart disease, and certain mental health conditions. In addition, as per a report published by the Center for Managing Chronic Disease, University of Michigan, more than 50% of the global population was estimated to be living with some form of chronic illness. The rising prevalence of these clinical conditions has resulted in dire need for the identification of effective therapeutic options. Despite advances in healthcare, there is an evident lack of permanent treatment solutions for many aforementioned diseases. Majority of the currently available treatment options focus on palliative care and are incapable of addressing the root cause of disease, therefore, are unable to improve quality of life of patients.
Since the first bone marrow transplant in 1950s, these regenerative cellular therapies have garnered significant attention within the biopharmaceutical industry. Over the years, advances in the field of cell biology and regenerative medicine have led to the development of a number of stem cell therapies, which are believed to possess the potential to address several unmet needs related to the treatment of a wide range of disease conditions. Stem cell-based treatments are known for their ability to replace damaged cells and tissues, thereby, curing affiliated disease symptoms. In fact, such interventions have also been shown to enable cell regeneration, restoring normal functioning capabilities in affected organs. Till date, nearly 25 stem cell-based therapies have been approved; popular examples include EYE-01M (2019), Alofisel® (2018), MACI (2016), Stempeucel® (2016) and Strimvelis® (2016). In addition, several such therapies are presently being evaluated across 540 active clinical trials worldwide. Further, recent studies suggest that stem cell therapies have demonstrated the potential to end the Coronavirus (COVID-19) pandemic. There are speculations, based on credible evidence, that infected patients treated with stem cells are more likely to survive the disease. Specifically, mesenchymal stem cells can be effectively used to improve patients' resistance to the SARS-CoV-2 virus induced pneumonia as these cells have the potential to repair damaged tissues in the patients’ respiratory system leading to speedy recovery. In fact, more than 20 biotech companies and academic institutes are focused on the development and testing of efficacy of stem cell therapies to combat this global pandemic. This emerging field of research has received significant capital investments from several big pharma companies and venture capital funds / investors. Despite the associated optimism, the growth of this market is stunted by a number of development and manufacturing related challenges, primarily revolving around the limited availability of the required expertise and infrastructure to produce such products. However, the availability of innovative technology platforms, large target patient population, encouraging clinical trial results, and extensive government support, the stem cell therapies market is poised to grow in the long-term.
The “Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
One of the key objectives of the report was to estimate the existing market size and identify the future opportunity for stem cell therapies over the next decade. The research, analyses and insights presented in this report are based on revenue generation trends based on the sales of approved stem cell therapies. The report also features the likely distribution of the current and forecasted opportunity within stem cell therapies market across [A] source of stem cells (allogeneic and autologous), [B] origin of stem cells (adult and embryonic), [C] type of stem cells (hematopoietic, mesenchymal, progenitor and others), [D] lineage of stem cells (adipose tissue, bone marrow and cord blood / embryonic stem cells), [E] route of administration (intraarticular, intracoronary, intramuscular, intramyocardial, intrathecal, intravenous, surgical implantation and others), [F] therapeutic area (autoimmune / inflammatory disorders, cardiovascular disorders, metabolic disorders, musculoskeletal disorders, oncological disorders, neurological disorders, ophthalmic disorders, and others), [H] end-users (ambulatory surgery centers, hospitals, and specialty clinics), and [G] key geographical regions (North America, Europe and Asia and rest of the world). To account for the uncertainties associated with the manufacturing of stem cell therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified
Contents
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of stem cell therapies market and their likely evolution in the short-mid-term and long term.
Chapter 3 provides a brief introduction to stem cell therapies, highlighting details regarding their development and administration. It includes information on various types of stem cell therapies (based on the source, potency and lineage of stem cells), modes of therapy administration and the disease indications targeted by such interventions. It also emphasizes on the challenges related to the development of such therapy candidates. In addition, it provides a detailed description of the regulatory landscape related to stem cell therapies across various geographies, such as the North America (primarily the US), Europe and other key global regions. Further, it includes an analysis of contemporary trends, as observed on the Google Trends portal, for the period 2015-2019 and insights from the recent news articles related to stem cell therapies indicating the increasing popularity of this upcoming field of research.
Chapter 4 includes information on over 280 stem cell-based therapies approved / under clinical development, providing information on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), phase of development (marketed, phase III, phase II, phase I), source of stem cells (allogeneic and autologous), origin of stem cells (adult and embryonic), type of stem cells (hematopoietic, mesenchymal, progenitor and others), stem cell lineage (amniotic fluid, adipose tissue, bone marrow, cardiosphere, chondrocytes, corneal tissue, cord blood, dental pulp, neural tissue placenta, peripheral blood, stromal cells and others), stem cell potency (multipotent and pluripotent), target indication(s), key therapeutic area(s), route of administration (intravenous, intramuscular, intraarticular, intramyocardial, intracoronary, intrathecal and others), and information on number of stem cells, special drug / therapy designation (if any), commercial geographical rights. It also focuses on the identification of contemporary market trends, depicted using five schematic representations, which include [A] a tree map representation of the various industry players involved in the development of stem cell therapies, distributed on the basis of the target therapeutic areas of pipeline candidates and size of the companies (small, mid-sized and large companies), [B] a schematic world map representation, highlighting the geographical locations of various industry players, [C] a bubble analysis comparing the leading players engaged in the generation of stem cell therapies, on the basis of parameters such as pipeline strength (based on the number of therapy candidates developed by a particular company, across different phases of development), number of target indications and the size of the developer company, [D] an insightful grid analysis, highlighting the distribution of therapy candidates on the basis of phase of development, source of stem cell and target therapeutic areas, and [E] an informative heptagon representation, highlighting the distribution of marketed / clinical stem cell therapies across popular target therapeutic areas (based on the number of therapy candidates across each target therapeutic areas). In addition, information on the various technology platforms being actively used for the development of stem cell therapies, has been provided.
Chapter 5 features detailed profiles of key industry players engaged in the development of stem cell-based therapies (shortlisted on the basis of number of pipeline products). Each profile features a brief overview of the company along with the information on year of establishment, company size, location of headquarters, key members of the executive team and financial information (if available), details on their respective product portfolio, and an informed future outlook.
Chapter 6 presents an assessment of over 20 most commonly targeted therapeutic indications and details of stem cell-based therapies being developed to treat them, highlighting disease specific epidemiological facts, contemporary methods of diagnosis, and currently available treatment options and their side-effects.
Chapter 7 features a proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.
Chapter 8 provides an analysis of more than 1,500 grants that were awarded to research institutes engaged in stem cell therapy-related projects, in the period between 2015 and 2019 (till November) based on the important parameters associated with grants, such as year of grant award, amount awarded, administration institute, funding institute center, funding institute center, support period, spending categorization, funding mechanism, grant type, responsible study section, focus area, prominent program officers, and type of recipient organizations. It also features a detailed analysis based on the types of stem cell (based on origin, source, potency and lineage) and therapeutic areas, along with a multivariate grant attractiveness analysis based on parameters, such as amount awarded, support period, grant type, number of indications under investigation.
Chapter 9 provides a detailed clinical trial analysis of more than 540 completed, ongoing and planned studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors (in terms of number of trials conducted), study focus, type of stem cells, target indication(s), target therapeutic area(s), enrolled patient population and regional distribution of trials.
Chapter 10 features a review of the key aspects related to the manufacturing of stem cell therapies, including [A] a detailed discussion on processes and protocols, highlighting the need to outsource various aspects of stem cell therapy development and manufacturing operations, [B] an assessment of the current market landscape of contract manufacturers, providing information on stem cell-focused service providers (such as year of establishment, company size, location of headquarters and manufacturing facilities), scale of stem cell manufacturing (commercial, clinician and preclinical), services offered in addition to manufacturing (culture development / set up, stem cell identification / validation, stem cell banking, regulatory consultancy, fill / finish, cryopreservation and stem cell logistics), source of stem cells (allogeneic and autologous), and origin of stem cells (adult and embryonic), [C] an insightful Harvey ball analysis to identify the key performance indicators / key considerations that industry stakeholders are likely to take into consideration while selecting a suitable CMO / CRO partner.
Chapter 11 presents a detailed market gap analysis in order to develop a realistic understanding of the demand and supply dynamics within this field, comparing both clinical and commercial capabilities of therapy developers and the availability and capabilities of contract manufacturers, across different geographies.
Chapter 12 features an elaborate discussion on the various strategies that can be adopted by stem cell therapy developers across different stages of product development and commercialization (prior to product launch, post-marketing, and near patent expiry), and the key strategies that have been adopted by drug developers for the commercialization of their proprietary product candidates.
Chapter 13 presents an insightful market forecast analysis, highlighting the likely growth of the stem cell therapy market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] source of stem cells (allogeneic and autologous), [B] origin of stem cells (adult and embryonic), [C] type of stem cells (hematopoietic, mesenchymal, progenitor and others), [D] lineage of stem cells (adipose tissue, bone marrow and cord blood / embryonic stem cells), [E] route of administration (intraarticular, intracoronary, intramuscular, intramyocardial, intrathecal, intravenous, surgical implantation and others), [F] therapeutic area (autoimmune / inflammatory disorders, cardiovascular disorders, metabolic disorders, musculoskeletal disorders, oncological disorders, neurological disorders, ophthalmic disorders, and others), [H] end users (ambulatory surgery centers, hospitals, and specialty clinics), and [G] key geographical regions (North America, Europe and Asia and rest of the world).
Chapter 14 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 15 features the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the stem cell therapy domain. We have inputs from William L Rust (Founder and Chief Executive Officer, Seraxis), Xuejun Huang Parsons (Chief Executive Officer, Xcelthera), Michel Revel (Co-Founder and Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Director, Business Development, Kadimastem), Kikuo Yasui (Director and Chief Operating Officer, Heartseed), Gustav Steinhoff (Director and Chairman, Department of Cardiac Surgery, University of Rostock), Gilles Devillers (President, Bio Elpida), Fiona Bellot (Business Development Manager, Roslin Cell Therapies), David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), and Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi).
Chapter 16 is an appendix that contains tabulated data and numbers for all the figures provided in the report.
Chapter 17 is an appendix that provides the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Stem Cell Therapies
3.2.1. Historical Evolution of Stem Cell Research
3.2.2. Classification of Stem Cells
3.2.2.1. Based on Source of Stem Cell
3.2.2.2. Based on Origin of Stem Cell
3.2.2.3. Based on Potency of Stem Cell
3.2.3. Administration of Stem Cell Therapies
3.2.4. Applications of Stem Cell Therapies
3.2.5. Challenges Associated with Development of Stem Cell Therapies
3.3. Regulatory Guidelines for Stem Cell Therapies
3.3.1. Current Scenario
3.3.2. Regulatory Guidelines in North America
3.3.3. Regulatory Guidelines in Europe
3.3.4. Regulatory Guidelines in Japan
3.4. Prevalent Trends Related to Stem Cell Therapies
3.4.1. Emerging Focus Areas
3.4.2. Key Historical Trends
3.4.3. Geographical Activity
3.5. Growth Drivers and Roadblocks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Stem Cell Therapies: Marketed and Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Source of Stem Cell
4.2.3. Analysis by Origin of Stem Cell
4.2.4. Analysis by Type of Stem Cell
4.2.5. Analysis by Lineage of Stem Cell
4.2.6. Analysis by Potency of Stem Cell
4.2.7. Analysis by Target Indication
4.2.8. Analysis by Therapeutic Area
4.2.9. Analysis by Route of Administration
4.3. Stem Cell Therapies: Additional Information
4.3.1. Information on Dosage and Commercial Rights
4.3.2. Information on Designations Awarded
4.4. Stem Cell Therapies: List of Technology Platforms
4.5. Stem Cell Therapies: List of Therapy Developers
4.5.1. Analysis by Year of Establishment
4.5.2. Analysis by Company Size
4.5.3. Analysis by Location of Headquarters
4.5.4. Analysis by Company Size and Location of Headquarters
4.5.5. Leading Drug Developers: Analysis by Number of Stem Cell Therapies
4.5.6. Leading Drug Developers: 4D Bubble Analysis based on Strength of Pipeline, Target Indication and Company Size
4.6. Heptagon Representation: Analysis by Phase of Development and Key Therapeutic Area
4.7. Grid Representation: Analysis by Phase of Development, Source of Stem Cell and Therapeutic Area
4.8. Tree Map Representation: Analysis by Therapeutic Area and Size of the Company
4.9. World Map Representation: Analysis of Regional Activity
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Anterogen
5.2.1. Company Overview
5.2.2. Product Portfolio: Clinical-Stage Stem Cell Therapies
5.2.3. Recent Developments and Future Outlook
5.3. Athersys
5.3.1. Company Overview
5.3.2. Product Portfolio: Clinical-Stage Stem Cell Therapies
5.3.3. Recent Developments and Future Outlook
5.4. CHA Biotech
5.4.1. Company Overview
5.4.2. Product Portfolio: Clinical-Stage Stem Cell Therapies
5.4.3. Recent Developments and Future Outlook
5.5. Cytopeutics
5.5.1. Company Overview
5.5.2. Product Portfolio: Clinical-Stage Stem Cell Therapies
5.5.3. Recent Developments and Future Outlook
5.6. Hope Biosciences
5.6.1. Company Overview
5.6.2. Product Portfolio: Clinical-Stage Stem Cell Therapies
5.6.3. Recent Developments and Future Outlook
5.7. Mesoblast
5.7.1. Company Overview
5.7.2. Product Portfolio: Clinical-Stage Stem Cell Therapies
5.7.3. Recent Developments and Future Outlook
5.8. Pluristem Therapeutics
5.8.1. Company Overview
5.8.2. Product Portfolio: Clinical-Stage Stem Cell Therapies
5.8.3. Recent Developments and Future Outlook
5.9. Takeda Pharmaceutical
5.9.1. Company Overview
5.9.2. Product Portfolio: Clinical-Stage Stem Cell Therapies
5.9.3. Recent Developments and Future Outlook
5.10. TICEBA
5.10.1. Company Overview
5.10.2. Product Portfolio: Clinical-Stage Stem Cell Therapies
5.10.3. Recent Developments and Future Outlook
6. KEY THERAPEUTIC AREAS
6.1. Chapter Overview
6.2. Autoimmune / Inflammatory Disorders
6.2.1. Crohn’s Disease
6.2.1.1. Disease Description
6.2.1.2. Epidemiology
6.2.1.3. Current Treatment Options
6.2.1.4. Side Effects of Current Treatment Options
6.2.1.5. Stem Cell Therapies for Crohn’s Disease
6.2.2. Ulcerative Colitis
6.2.2.1. Disease Description
6.2.2.2. Epidemiology
6.2.2.3. Current Treatment Options
6.2.2.4. Side Effects of Current Treatment Options
6.2.2.5. Stem Cell Therapies for Ulcerative Colitis
6.3. Cardiovascular Disorders
6.3.1. Critical Limb Ischemia
6.3.1.1. Disease Description
6.3.1.2. Epidemiology
6.3.1.3. Current Treatment Options
6.3.1.3.1. Pharmacological Interventions
6.3.1.3.2. Endovascular Treatments
6.3.1.3.3. Surgical Interventions
6.3.1.4. Stem Cell Therapies for Critical Limb Ischemia
6.3.2. Heart Failure
6.3.2.1. Disease Description
6.3.2.2. Epidemiology
6.3.2.3. Current Treatment Options
6.3.2.3.1. Pharmacological Interventions
6.3.2.3.2. Therapeutic Devices
6.3.2.3.3. Surgical Interventions
6.3.2.4. Stem Cell Therapies for Heart Failure
6.3.3. Myocardial Infarction
6.3.3.1. Disease Description
6.3.3.2. Epidemiology
6.3.3.3. Current Treatment Options
6.3.3.3.1. Pharmacological Interventions
6.3.3.3.2. Surgical Interventions
6.3.3.4. Stem Cell Therapies for Myocardial Infarction
6.4. Dermatological Disorders
6.4.1. Acne Vulgaris
6.4.1.1. Disease Description
6.4.1.2. Epidemiology
6.4.1.3. Current Treatment Options
6.4.1.4. Side Effects of Current Treatment Options
6.4.1.5. Stem Cell Therapies for Acne Vulgaris
6.5. Metabolic Disorders
6.5.1. Diabetes
6.5.1.1. Disease Description
6.5.1.2. Associated Health Risks / Complications
6.5.1.3. Epidemiology
6.5.1.4. Disease Diagnosis
6.5.1.5. Current Treatment Options
6.5.1.5.1. Insulin Therapies
6.5.1.5.2. Non-Insulin Therapies
6.5.1.6. Side Effects of Current Treatment Options
6.5.1.7. Stem Cell Therapies for Diabetes
6.5.2. Non-alcoholic Steatohepatitis (NASH)
6.5.2.1. Disease Description
6.5.2.2. Epidemiology
6.5.2.3. Current Treatment Options
6.5.2.4. Stem Cell Therapies for NASH
6.6. Oncological Disorders
6.6.1. Bladder Cancer
6.6.1.1. Disease Description
6.6.1.2. Epidemiology
6.6.1.3. Current Treatment Options
6.6.1.4. Stem Cell Therapies for Bladder Cancer
6.6.2. Breast Cancer
6.6.2.1. Disease Description
6.6.2.2. Epidemiology
6.6.2.3. Current Treatment Options
6.6.2.4. Stem Cell Therapies for Breast Cancer
6.6.3. Colorectal Cancer
6.6.3.1. Disease Description
6.6.3.2. Epidemiology
6.6.3.3. Current Treatment Options
6.6.3.4. Side Effects of Current Treatment Options
6.6.3.5. Stem Cell Therapies for Colorectal Cancer
6.6.4. Kidney Cancer
6.6.4.1. Disease Description
6.6.4.2. Epidemiology
6.6.4.3. Current Treatment Options
6.6.4.4. Stem Cell Therapies for Kidney Cancer
6.6.5. Liver Cancer
6.6.5.1. Introduction
6.6.5.2. Epidemiology
6.6.5.3. Current Treatment Options
6.6.5.4. Stem Cell Therapies for Liver Cancer
6.6.6. Lung Cancer
6.6.6.1. Disease Description
6.6.6.2. Epidemiology
6.6.6.3. Current Treatment Options
6.6.6.4. Side Effects of Current Treatment Options
6.6.6.5. Stem Cell Therapies for Lung Cancer
6.6.7. Ovarian Cancer
6.6.7.1. Disease Description
6.6.7.2. Epidemiology
6.6.7.3. Current Treatment Options
6.6.7.4. Stem Cell Therapies for Ovarian Cancer
6.6.8. Pancreatic Cancer
6.6.8.1. Disease Description
6.6.8.2. Epidemiology
6.6.8.3. Current Treatment Options
6.6.8.4. Stem Cell Based Therapies for Pancreatic Cancer
6.7. Neurological Disorders
6.7.1. Alzheimer’s Disease
6.7.1.1. Disease Description
6.7.1.2. Epidemiology
6.7.1.3. Symptoms of the Disease
6.7.1.4. Causes of Alzheimer’s Disease
6.7.1.5. Stages of Alzheimer’s Disease
6.7.1.6. Current Treatment Options
6.7.1.7. Stem Cell Therapies for Alzheimer’s Disease
6.7.2. Parkinson’s Disease
6.7.2.1. Disease Description
6.7.2.2. Epidemiology
6.7.2.3. Current Treatment Options
6.7.2.3.1. Pharmacological Management of Parkinson’s Disease
6.7.2.3.2. Non-Pharmacological Management of Parkinson’s Disease
6.7.2.3.3. Management of Parkinson’s Disease Using Dietary Supplements
6.7.2.4. Stem Cell Therapies for Parkinson’s Disease
7. ASSESSMENT OF RELATIVE COMPETITION AND GROWTH
7.1. Chapter Overview
7.2. Assumptions and Methodology
7.3. Analysis of Relative Competition and Growth Opportunities
7.3.1. Established Therapeutic Areas in Emerging Regions
7.3.2. Established Therapeutic Areas in Established Regions
7.3.3. Emerging Therapeutic Areas in Emerging Regions
7.3.4. Emerging Therapeutic Areas in Established Regions
8. ACADEMIC GRANTS ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Stem Cell Therapies: Analysis of Grants Awarded by the National Institutes of Health (NIH)
8.3.1. Analysis by Year of Award
8.3.2. Analysis by Amount Awarded
8.3.3. Analysis by Administering Institute Center
8.3.4. Analysis by Funding Institute Center
8.3.5. Analysis by Support Period
8.3.6. Analysis by Funding Institute Center and Support Period
8.3.7. Most Popular NIH Spending Categorizations
8.3.8. Analysis by Funding Mechanism
8.3.9. Emerging Focus Areas
8.3.10. Analysis by Source of Stem Cell
8.3.11. Analysis by Origin of Stem Cell
8.3.12. Analysis by Type of Stem Cell
8.3.13. Analysis by Lineage of Stem Cell
8.3.14. Analysis by Potency of Stem Cell
8.3.15. Analysis by Therapeutic Area
8.3.16. Analysis by Type of Grant Application
8.3.17. Popular NIH Departments
8.3.18. Analysis by Study Section
8.3.19. Analysis by Types of Recipient Organizations
8.3.20. Popular Recipient Organizations
8.3.21. Analysis by Grant Mechanism
8.3.22. Prominent Program Officers
8.3.23. Regional Distribution of Recipient Organizations
8.4. Grant Attractiveness Analysis
9. CLINICAL TRIAL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Stem Cell Therapies: Clinical Trial Analysis
9.3.1. Analysis by Trial Registration Year
9.3.2. Analysis by Trial Phase
9.3.3. Analysis by Number of Patients Enrolled by Trial Registration Year
9.3.4. Analysis by Study Design
9.3.5. Analysis by Trial Recruitment Status
9.3.6. Analysis by Sponsor / Collaborator
9.3.7. Leading Industry Sponsors: Based on Number of Registered Trials
9.3.8. Analysis by Trial Focus
9.3.9. Analysis by Type of Stem Cell
9.3.10. Analysis by Therapeutic Area
9.3.11. Analysis by Type of Stem Cell and Therapeutic Area
9.3.12. Geographical Analysis by Number of Clinical Trials
9.3.13. Geographical Analysis by Trial Recruitment Status
9.3.14. Geographical Analysis by Enrolled Patient Population
10. STEM CELL MANUFACTURING MARKET LANDSCAPE AND KPIs FOR EVALUATING CONTRACT SERVICES PARTNERS
10.1. Chapter Overview
10.2. Stem Cell Therapy Manufacturing
10.2.1. Need for Stem Cell Therapy Contract Manufacturing
10.2.2. Advantages of Outsourcing Stem Cell Therapy Manufacturing
10.2.3. Guidelines for Selecting a Contract Manufacturing Organization (CMO) Partner
10.2.4. Stem Cell Therapy CMOs: List of Industry Players
10.2.4.1. Analysis by Year of Establishment
10.2.4.2. Analysis by Company Size
10.2.4.3. Analysis by Scale of Stem Cell Manufacturing
10.2.4.4. Analysis by Location of Headquarters
10.2.4.5. Analysis by Location of Manufacturing Facilities
10.2.4.6. Analysis by Types of Services Offered
10.2.4.7. Analysis by Source and Origin of Stem Cell
10.2.5. Stem Cell Therapy CMOs: List of Non-Industry Players
10.2.5.1. Analysis by Year of Establishment
10.2.5.2. Analysis by Scale of Stem Cell Manufacturing
10.2.5.3. Analysis by Location of Headquarters
10.2.5.4. Analysis by Location of Manufacturing Facilities
10.2.5.5. Analysis by Types of Services Offered
10.2.5.6. Analysis by Source and Origin Stem Cell
10.3. Stem Cell Therapy Manufacturing: KPI Analysis
10.3.1. KPI Definitions
10.3.1.1. Financial Indicators
10.3.1.1.1. Big Pharma Perspective
10.3.1.1.2. Contract Manufacturers’ Perspective
10.3.1.2. Process and Capability Indicators
10.3.1.2.1. Big Pharma Perspective
10.3.1.2.2. Contract Manufacturers’ Perspective
10.3.1.3. Market Reputation Indicators
10.3.1.3.1. Big Pharma Perspective
10.3.1.3.2. Contract Manufacturers’ Perspective
10.4. Concluding Remarks
11. STEM CELL THERAPY DEVELOPERS AND CMOs: OPPORTUNITY ASSESSMENT
11.1. Chapter Overview
11.2. Therapy Developers and CMOs in North America
11.2.1. Gap Analysis by Scale of Stem Cell Manufacturing
11.2.2. Gap Analysis by Source of Stem Cell
11.2.3. Gap Analysis by Origin of Stem Cell
11.3. Therapy Developers and CMOs in Europe
11.3.1. Gap Analysis by Scale of Stem Cell Manufacturing
11.3.2. Gap Analysis by Source of Stem Cell
11.3.3. Gap Analysis by Origin of Stem Cell
11.4. Therapy Developers and CMOs in Asia-Pacific and Rest of the World
11.4.1. Gap Analysis by Scale of Stem Cell Manufacturing
11.4.2. Gap Analysis by Source of Stem Cell
11.4.3. Gap Analysis by Origin of Stem Cell
11.5. Concluding Remarks
12. KEY COMMERCIALIZATION STRATEGIES
12.1. Chapter Overview
12.2. Successful Drug Launch Strategy: ROOTS Framework
12.3. Successful Drug Launch Strategy: Product Differentiation
12.4. Commonly Adopted Commercialization Strategies based on Stage of Product Development
12.5. Key Approved Stem Cell Therapies: Profiles
12.5.1. CARTISTEM®
12.5.2. HiQCell®
12.5.3. Prochymal®
12.5.4. Strimvelis®
12.6. Key Commercialization Strategies Adopted by Stem Cell Therapy Developers
12.6.1. Strategies Adopted before Therapy Approval
12.6.1.1. Participation in Global Events
12.6.1.2. Collaboration with Stakeholders and Pharmaceutical Firms
12.6.1.3. Seeking Approval for Multiple Target Indications
12.6.1.4. Seeking Special Therapy Designations and Other Credentials
12.6.1.5. Leveraging Uniqueness to Establish Competitive Edge
12.6.1.6. Anticipation of Likely Market Dynamics and Trends
12.6.1.7. Outsourcing Manufacturing Operations
12.6.2. Strategies Adopted Post Therapy Approval
12.6.2.1. Geographical Expansion
12.6.2.2. Participation in Global Events
12.6.2.3. Patient Assistance Programs
12.6.2.4. Miscellaneous Programs
12.7. Opportunities and Challenges with Unapproved Therapies
12.8. Concluding Remarks
13. MARKET FORECAST
13.1. Chapter Overview
13.2. Scope and Limitations
13.3. Forecast Methodology and Key Assumptions
13.4. Overall Stem Cell Therapies Market, 2020-2030
13.4.1. Stem Cell Therapies Market: Distribution by Source of Stem Cell
13.4.1.1. Stem Cell Therapies Market for Allogeneic Therapies, 2020-2030
13.4.1.2. Stem Cell Therapies Market for Autologous Therapies, 2020-2030
13.4.2. Stem Cell Therapies Market: Distribution by Origin of Stem Cell
13.4.2.1. Stem Cell Therapies Market for Adult Stem Cells, 2020-2030
13.4.2.2. Stem Cell Therapies Market for Embryonic Stem Cells, 2020-2030
13.4.3. Stem Cell Therapies Market: Distribution by Type of Stem Cell
13.4.3.1. Stem Cell Therapies Market for Hematopoietic Stem Cells, 2020-2030
13.4.3.2. Stem Cell Therapies Market for Mesenchymal Stem Cells, 2020-2030
13.4.3.3. Stem Cell Therapies Market for Progenitor Cells, 2020-2030
13.4.3.4. Stem Cell Therapies Market for Others, 2020-2030
13.4.4. Stem Cell Therapies Market: Distribution by Lineage of Stem Cell
13.4.4.1. Stem Cell Therapies Market for Adipose Tissue Derived Stem Cells, 2020-2030
13.4.4.2. Stem Cell Therapies Market for Bone Marrow Derived Stem Cells, 2020-2030
13.4.4.3. Stem Cell Therapies Market for Cord Blood Derived Stem Cells, 2020-2030
13.4.4.4. Stem Cell Therapies Market for Others, 2020-2030
13.4.5. Stem Cell Therapies Market: Distribution by Route of Administration
13.4.5.1. Stem Cell Therapies Market for Intraarticular Therapies, 2020-2030
13.4.5.2. Stem Cell Therapies Market for Intracoronary Therapies, 2020-2030
13.4.5.3. Stem Cell Therapies Market for Intramuscular Therapies, 2020-2030
13.4.5.4. Stem Cell Therapies Market for Intramyocardial Therapies, 2020-2030
13.4.5.5. Stem Cell Therapies Market for Intrathecal Therapies, 2020-2030
13.4.5.6. Stem Cell Therapies Market for Intravenous Therapies, 2020-2030
13.4.5.7. Stem Cell Therapies Market for Surgical Implants, 2020-2030
13.4.5.7. Stem Cell Therapies Market for Others, 2020-2030
13.4.6. Stem Cell Therapies Market: Distribution by Therapeutic Area
13.4.6.1. Stem Cell Therapies Market for Autoimmune / Inflammatory Disorders, 2020-2030
13.4.6.2. Stem Cell Therapies Market for Cardiovascular Disorders, 2020-2030
13.4.6.3. Stem Cell Therapies Market for Metabolic Disorders, 2020-2030
13.4.6.4. Stem Cell Therapies Market for Musculoskeletal Disorders, 2020-2030
13.4.6.5. Stem Cell Therapies Market for Neurological Disorders, 2020-2030
13.4.6.6. Stem Cell Therapies Market for Oncological Disorders, 2020-2030
13.4.6.7. Stem Cell Therapies Market for Ophthalmic Disorders, 2020-2030
13.4.6.8. Stem Cell Therapies Market for Others, 2020-2030
13.4.7. Stem Cell Therapies Market: Distribution by End-Users
13.4.7.1. Stem Cell Therapies Market for Ambulatory Surgery Centers, 2020-2030
13.4.7.2. Stem Cell Therapies Market for Hospitals, 2020-2030
13.4.7.3. Stem Cell Therapies Market for Specialty Clinics, 2020-2030
13.4.8. Stem Cell Therapies Market: Distribution by Key Geographical Regions
13.4.8.1. Stem Cell Therapies Market in North America, 2020-2030
13.4.8.2. Stem Cell Therapies Market in Europe, 2020-2030
13.4.8.3. Stem Cell Therapies Market in Asia-Pacific and Rest of the World, 2020-2030
13.5. Concluding Remarks
14. CONCLUSION
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Seraxis
15.2.1. Company Snapshot
15.2.2. Interview Transcript: William L Rust, Founder and Chief Executive Officer
15.3. Xcelthera
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Xuejun Huang Parsons, Chief Executive Officer
15.4. Kadimastem
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Michel Revel, Co-Founder / Chief Scientist and Galit Mazooz-Perlmuter, Director, Business Development
15.5. Heartseed
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Kikuo Yasui, Director and Chief Operating Officer
15.6. University of Rostock
15.6.1. Organization Snapshot
15.6.2. Interview Transcript: Gustav Steinhoff, Director and Chairman, Department of Cardiac Surgery
15.7. Bio Elpida
15.7.1. Company Snapshot
15.7.2. Interview Transcript: Gilles Devillers, President
15.8. Roslin Cell Therapies
15.8.1. Company Snapshot
15.8.2. Interview Transcript: Fiona Bellot, Business Development Manager
15.9. University of Minnesota
15.9.1. Organization Snapshot
15.9.2. Interview Transcript: David Mckenna, Professor and American Red Cross Chair in Transfusion Medicine
15.10. Waisman Biomanufacturing
15.10.1. Company Snapshot
15.10.2. Interview Transcript: Brian Dattilo, Manager of Business Development
15.11. YposKesi
15.11.1. Company Snapshot
15.11.2. Interview Transcript: Mathilde Girard, Department Leader, Cell Therapy Innovation and Development
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Cellular Lineages Used for the Isolation of Stem Cells
Figure 3.2 Steps Involved in the Development and Administration of Stem Cell Therapies Figure 3.3
Figure 3.4 Classification of Stem Cells
Figure 3.5 Classification based on Source of Stem Cell
Figure 3.6 Differences between Allogeneic and Autologous Stem Cell Therapies
Figure 3.7 Classification based on Origin of Stem Cell
Figure 3.8 Classification based on Potency of Stem Cell
Figure 3.9 Key Application Areas for Stem Cell Therapies
Figure 3.10 Emerging Focus Areas: Google News
Figure 3.11 Historical Timeline: Analysis of Google Trends
Figure 3.12 Geographical Activity: Analysis of Google Trends
Figure 3.13 Stem Cell Therapies: Key Growth Drivers and Roadblocks
Figure 4.1 Stem Cell Therapies: Distribution by Phase of Development
Figure 4.2 Stem Cell Therapies: Distribution by Source of Stem Cell
Figure 4.3 Stem Cell Therapies: Distribution by Origin of Stem Cell
Figure 4.4 Stem Cell Therapies: Distribution by Type of Stem Cell
Figure 4.5 Stem Cell Therapies: Distribution by Lineage of Stem Cell
Figure 4.6 Stem Cell Therapies: Distribution by Potency of Stem Cell
Figure 4.7 Stem Cell Therapies: Distribution by Target Indication
Figure 4.8 Stem Cell Therapies: Distribution by Therapeutic Area
Figure 4.9 Stem Cell Therapies: Distribution by Route of Administration
Figure 4.10 Stem Cell Therapy Developers: Distribution by Year of Establishment
Figure 4.11 Stem Cell Therapy Developers: Distribution by Company Size
Figure 4.12 Stem Cell Therapy Developers: Distribution by Location of Headquarters
Figure 4.13 Stem Cell Therapy Developers: Distribution by Company Size and Location of Headquarters
Figure 4.14 Leading Stem Cell Therapy Developers: Distribution by Number of Stem Cell Therapies
Figure 4.15 Leading Stem Cell Therapy Developers: 4D Bubble Analysis based on Strength of Pipeline, Number of Therapies, Target Indication and Company Size
Figure 4.16 Heptagon Representation: Distribution by Phase of Development and Key Therapeutic Area
Figure 4.17 Grid Representation: Distribution by Phase of Development, Source of Stem Cell and Therapeutic Area
Figure 4.18 Tree Map Representation: Distribution by Therapeutic Area and Size of the Company
Figure 4.19 World Map Representation: Regional Activity
Figure 6.1 Critical Limb Ischemia: Risk Factors
Figure 6.2 Critical Limb Ischemia: Symptoms
Figure 6.3 Heart Failure: Types
Figure 6.4 Heart Failure: Risk Factors
Figure 6.5 Heart Failure: Symptoms
Figure 6.6 Myocardial Infarction: Risk Factors
Figure 6.7 Myocardial Infarction: Symptoms
Figure 6.8 Diabetes: Diagnostic Limits for Plasma Glucose Levels
Figure 6.9 Diabetes: Non-Insulin Therapies
Figure 6.10 Bladder Cancer: Global Epidemiological Distribution
Figure 6.11 Breast Cancer: Global Epidemiological Distribution
Figure 6.12 Kidney Cancer: Global Epidemiological Distribution
Figure 6.13 Liver Cancer: Global Epidemiological Distribution
Figure 6.14 Lung Cancer: Global Epidemiological Distribution
Figure 6.15 Ovarian Cancer: Global Epidemiological Distribution
Figure 6.16 Pancreatic Cancer: Global Epidemiological Distribution
Figure 6.17 Dementia: Global Epidemiological Distribution
Figure 6.18 Alzheimer’s Disease: Signs and Symptoms
Figure 6.19 Alzheimer’s Disease: Normal Brain versus Diseased Brain
Figure 6.20 Alzheimer’s Disease: Phases of Disease Progression
Figure 6.21 Parkinson’s Disease: Gender-wise Incidence Rates
Figure 6.22 Parkinson’s Disease: Non-Pharmacological Treatment Options
Figure 6.23 Parkinson’s Disease: Surgical Interventions
Figure 6.24 Parkinson’s Disease: Dietary Supplements
Figure 7.1 Relative Competition and Growth Opportunities Related to Stem Cell Therapies: Analytical Output
Figure 7.2 Relative Competition and Growth Opportunities Related to Established Therapeutic Areas in Emerging Regions
Figure 7.3 Relative Competition and Growth Opportunities Related to Established Therapeutic Areas in Established Regions
Figure 7.4 Relative Competition and Growth Opportunities Related to Emerging Therapeutic Areas in Emerging Regions
Figure 7.5 Relative Competition and Growth Opportunities Related to Emerging Therapeutic Areas in Established Regions
Figure 8.1 Grant Analysis: Cumulative Trend by Year of Award, 2015-2019
Figure 8.2 Grant Analysis: Cumulative Trend by Amount Awarded, 2015-2019 (USD Million)
Figure 8.3 Grant Analysis: Distribution by Administering Institute Center
Figure 8.4 Grant Analysis: Distribution by Funding Institute Center
Figure 8.5 Grant Analysis: Distribution by Support Period
Figure 8.6 Grant Analysis: Distribution by Funding Institute Center and Support Period
Figure 8.7 Grant Analysis: Most Popular NIH Funding Categorizations
Figure 8.8 Grant Analysis: Distribution by Funding Mechanism
Figure 8.9 Grant Analysis: Emerging Focus Areas
Figure 8.10 Grant Analysis: Distribution by Source of Stem Cell
Figure 8.11 Grant Analysis: Distribution by Origin of Stem Cell
Figure 8.12 Grant Analysis: Distribution by Type of Stem Cell
Figure 8.13 Grant Analysis: Year-Wise Trend in Activity for Different Types of Stem Cells
Figure 8.14 Grant Analysis: Year-Wise Trend in Amount Awarded for Different Types of Stem Cells (USD Million)
Figure 8.15 Grant Analysis: Distribution by Lineage of Stem Cell
Figure 8.16 Grant Analysis: Distribution by Potency of Stem Cell
Figure 8.17 Grant Analysis: Distribution by Therapeutic Area
Figure 8.18 Grant Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
Figure 8.19 Grant Analysis: Year-Wise Trend in Amount Awarded for Popular Therapeutic Areas (USD Million)
Figure 8.20 Grant Analysis: Distribution by Type of Grant Application
Figure 8.21 Grant Analysis: Popular NIH Departments
Figure 8.22 Grant Analysis: Distribution by Study Section
Figure 8.23 Grant Analysis: Types of Recipient Organizations
Figure 8.24 Grant Analysis: Popular Recipient Organizations
Figure 8.25 Grant Analysis: Distribution by Grant Mechanism
Figure 8.26 Grant Analysis: Prominent Program Officers
Figure 8.27 Grant Analysis: Regional Distribution of Recipient Organizations
Figure 8.28 Grant Analysis: Categorizations based on Weighted Attractiveness Scores
Figure 8.29 Grant Analysis: Multivariate Grant Attractiveness Analysis
Figure 9.1 Clinical Trial Analysis: Scope and Methodology
Figure 9.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 9.3 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2019
Figure 9.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 9.5 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, 2011-2019
Figure 9.6 Clinical Trial Analysis: Distribution by Study Design
Figure 9.7 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Figure 9.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 9.9 Clinical Trial Analysis: Leading Industry Players
Figure 9.10 Clinical Trial Analysis: Distribution by Focus Area
Figure 9.11 Clinical Trial Analysis: Distribution by Type of Stem Cell
Figure 9.12 Clinical Trial Analysis: Cumulative Distribution by Type of Stem Cell and Trial Registration Year
Figure 9.13 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 9.14 Clinical Trial Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
Figure 9.15 Clinical Trial Analysis: Distribution by Patient Enrollment and Therapeutic Area
Figure 9.16 Clinical Trial Analysis: Year-Wise Trend in Patient Enrollment (in thousands) for Popular Therapeutic Areas
Figure 9.17 Clinical Trial Analysis: Distribution by Type of Stem Cell and Therapeutic Area
Figure 9.18 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Figure 9.19 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
Figure 9.20 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 10.1 Key Steps Involved in the Manufacturing of Stem Cell Therapies
Figure 10.2 Stem Cell Therapy CMOs (Industry): Distribution by Year of Establishment
Figure 10.3 Stem Cell Therapy CMOs (Industry): Distribution by Company Size
Figure 10.4 Stem Cell Therapy CMOs (Industry): Distribution by Scale of Manufacturing
Figure 10.5 Stem Cell Therapy CMOs (Industry): Distribution by Location of Headquarters
Figure 10.6 Stem Cell Therapy CMOs (Industry): Distribution by Location of Manufacturing Facilities
Figure 10.7 Stem Cell Therapy CMOs (Industry): Distribution by Types of Services Offered
Figure 10.8 Stem Cell Therapy CMOs (Industry): Distribution by Source of Stem Cell
Figure 10.9 Stem Cell Therapy CMOs (Industry): Distribution by Origin of Stem Cell
Figure 10.10 Stem Cell Therapy CMOs (Non-Industry): Distribution by Year of Establishment
Figure 10.11 Stem Cell Therapy CMOs (Non-Industry): Distribution by Scale of Manufacturing
Figure 10.12 Stem Cell Therapy CMOs (Non-Industry): Distribution by Location of Headquarters
Figure 10.13 Stem Cell Therapy CMOs (Non-Industry): Distribution by Location of Manufacturing Facilities
Figure 10.14 Stem Cell Therapy CMOs (Non-Industry): Distribution by Types of Services Offered
Figure 10.15 Stem Cell Therapy CMOs (Non-Industry): Distribution by Source of Stem Cell
Figure 10.16 Stem Cell Therapy CMOs (Non-Industry): Distribution by Origin of Stem Cell
Figure 10.17 Financial Indicators: Comparative Analysis of KPIs Considered by Big Pharma Companies
Figure 10.18 Financial Indicators: Big Pharma Perspective
Figure 10.19 Financial Indicators: Contract Manufacturers’ Perspective
Figure 10.20 Process / Capability Indicators: Big Pharma Perspective
Figure 10.21 Process / Capability Indicators: Contract Manufacturers’ Perspective
Figure 10.22 Market Reputation Indicators: Comparative Analysis of KPIs of Big Pharma Companies
Figure 10.23 Market Reputation Indicators: Big Pharma Perspective
Figure 10.24 Market Reputation Indicators: Contract Manufacturers’ Perspective
Figure 11.1 Opportunity Assessment in North America: Gap Analysis by Scale of Stem Cell Manufacturing
Figure 11.2 Opportunity Assessment in North America: Gap Analysis by Source of Stem Cell
Figure 11.3 Opportunity Assessment in North America: Gap Analysis by Origin of Stem Cell
Figure 11.4 Opportunity Assessment in Europe: Gap Analysis by Scale of Stem Cell Manufacturing
Figure 11.5 Opportunity Assessment in Europe: Gap Analysis by Source of Stem Cell
Figure 11.6 Opportunity Assessment in Europe: Gap Analysis by Origin of Stem Cell
Figure 11.7 Opportunity Assessment in Asia-Pacific and Rest of the World: Gap Analysis by Scale of Stem Cell Manufacturing
Figure 11.8 Opportunity Assessment in Asia-Pacific and Rest of the World: Gap Analysis by Source of Stem Cell
Figure 11.9 Opportunity Assessment in Asia-Pacific and Rest of the World: Gap Analysis by Origin of Stem Cell
Figure 11.10 Stem Cell Therapy Developers and CMOs: Mapping Regional Presence
Figure 11.11 Stem Cell Therapy Developers and CMOs: Mapping Capabilities
Figure 12.1 Successful Drug Launch Strategy: ROOTS Framework
Figure 12.2 Commonly Adopted Commercialization Strategies based on Development Stage of the Product
Figure 12.3 Harvey Ball Analysis: Commercialization Strategies Adopted by Companies Focused on Stem Cell Therapies
Figure 12.4 Approved Stem Cell Therapies: Historical Timeline of Geographical Expansion
Figure 13.1 Overall Stem Cell Therapies Market, 2020-2030 (USD Million)
Figure 13.2 Stem Cell Therapies Market: Distribution by Source of Stem Cell, 2020 and 2030
Figure 13.3 Stem Cell Therapies Market for Allogeneic Therapies, 2020-2030 (USD Million)
Figure 13.4 Stem Cell Therapies Market for Autologous Therapies, 2020-2030 (USD Million)
Figure 13.5 Stem Cell Therapies Market: Distribution by Origin of Stem Cell, 2020 and 2030
Figure 13.6 Stem Cell Therapies Market for Adult Stem Cells, 2020-2030 (USD Million)
Figure 13.7 Stem Cell Therapies Market for Embryonic Stem Cells, 2020-2030 (USD Million)
Figure 13.8 Stem Cell Therapies Market: Distribution by Type of Stem Cell, 2020 and 2030
Figure 13.9 Stem Cell Therapies Market for Hematopoietic Stem Cells, 2020-2030 (USD Million)
Figure 13.10 Stem Cell Therapies Market for Mesenchymal Stem Cells, 2020-2030 (USD Million)
Figure 13.11 Stem Cell Therapies Market for Progenitor Cells, 2020-2030 (USD Million)
Figure 13.12 Stem Cell Therapies Market for Others, 2020-2030 (USD Million)
Figure 13.13 Stem Cell Therapies Market: Distribution by Lineage of Stem Cell, 2020 and 2030
Figure 13.14 Stem Cell Therapies Market for Adipose Tissue Derived Stem Cells, 2020-2030 (USD Million)
Figure 13.15 Stem Cell Therapies Market for Bone Marrow Derived Stem Cells, 2020-2030 (USD Million)
Figure 13.16 Stem Cell Therapies Market for Cord Blood Derived Stem Cells, 2020-2030 (USD Million)
Figure 13.17 Stem Cell Therapies Market for Others, 2020-2030 (USD Million)
Figure 13.18 Stem Cell Therapies Market: Distribution by Route of Administration, 2020 and 2030
Figure 13.19 Stem Cell Therapies Market for Intraarticular Therapies, 2020-2030 (USD Million)
Figure 13.20 Stem Cell Therapies Market for Intracoronary Therapies, 2020-2030 (USD Million)
Figure 13.21 Stem Cell Therapies Market for Intramuscular Therapies, 2020-2030 (USD Million)
Figure 13.22 Stem Cell Therapies Market for Intramyocardial Therapies, 2020-2030 (USD Million)
Figure 13.23 Stem Cell Therapies Market for Intrathecal Therapies, 2020-2030 (USD Million)
Figure 13.24 Stem Cell Therapies Market for Intravenous Therapies, 2020-2030 (USD Million)
Figure 13.25 Stem Cell Therapies Market for Surgical Implants, 2020-2030 (USD Million)
Figure 13.26 Stem Cell Therapies Market for Others, 2020-2030 (USD Million)
Figure 13.27 Stem Cell Therapies Market: Distribution by Therapeutic Area, 2020 and 2030
Figure 13.28 Stem Cell Therapies Market for Autoimmune / Inflammatory Disorders, 2020-2030 (USD Million)
Figure 13.29 Stem Cell Therapies Market for Cardiovascular Disorders, 2020-2030 (USD Million)
Figure 13.30 Stem Cell Therapies Market for Metabolic Disorders, 2020-2030 (USD Million)
Figure 13.31 Stem Cell Therapies Market for Musculoskeletal Disorders, 2020-2030 (USD Million)
Figure 13.32 Stem Cell Therapies Market for Neurological Disorders, 2020-2030 (USD Million)
Figure 13.33 Stem Cell Therapies Market for Oncological Disorders, 2020-2030 (USD Million)
Figure 13.34 Stem Cell Therapies Market for Ophthalmic Disorders, 2020-2030 (USD Million)
Figure 13.35 Stem Cell Therapies Market for Others, 2020-2030 (USD Million)
Figure 13.36 Stem Cell Therapies Market: Distribution by End-Users, 2020 and 2030
Figure 13.37 Stem Cell Therapies Market for Ambulatory Surgery Centers, 2020-2030 (USD Million)
Figure 13.38 Stem Cell Therapies Market for Hospitals, 2020-2030 (USD Million)
Figure 13.39 Stem Cell Therapies Market for Specialty Clinics, 2020-2030 (USD Million)
Figure 13.40 Stem Cell Therapies Market: Distribution by Key Geographical Regions, 2020 and 2030
Figure 13.41 Stem Cell Therapies Market in North America, 2020-2030 (USD Million)
Figure 13.42 Stem Cell Therapies Market in Europe, 2020-2030 (USD Million)
Figure 13.43 Stem Cell Therapies Market in Asia-Pacific and Rest of the World, 2020-2030 (USD Million)
Table 3.1 Differences between Stem Cell Therapies and Other Biologics
Table 4.1 Stem Cell Therapies: Marketed and Development Pipeline
Table 4.2 Stem Cell Therapies Pipeline: Information on Target Indication, Therapeutic Area and Route of Administration
Table 4.3 Stem Cell Therapies Pipeline: Information on Dosage and Commercial Rights
Table 4.4 Stem Cell Therapies Pipeline: Information on Special Designations
Table 4.5 Stem Cell Therapies Pipeline: Information on Technology Platforms
Table 4.6 Stem Cell Therapies Pipeline: List of Therapy Developers
Table 5.1 List of Companies Profiles
Table 5.2 Anterogen: Company Profile
Table 5.3 Product Portfolio: Clinical-Stage Stem Cell Therapies
Table 5.4 Anterogen: Recent Developments and Future Outlook
Table 5.5 Athersys: Company Profile
Table 5.6 Product Portfolio: Clinical-Stage Stem Cell Therapies
Table 5.7 Athersys: Recent Developments and Future Outlook
Table 5.8 CHA Biotech: Company Profile
Table 5.9 Product Portfolio: Clinical-Stage Stem Cell Therapies
Table 5.10 CHA Biotech: Recent Developments and Future Outlook
Table 5.11 Cytopeutics: Company Profile
Table 5.12 Product Portfolio: Clinical-Stage Stem Cell Therapies
Table 5.13 Cytopeutics: Recent Developments and Future Outlook
Table 5.14 Hope Biosciences: Company Profile
Table 5.15 Product Portfolio: Clinical-Stage Stem Cell Therapies
Table 5.16 Hope Biosciences: Recent Developments and Future Outlook
Table 5.17 Mesoblast: Company Profile
Table 5.18 Product Portfolio: Clinical-Stage Stem Cell Therapies
Table 5.19 Mesoblast: Recent Developments and Future Outlook
Table 5.20 Pluristem Therapeutics: Company Profile
Table 5.21 Product Portfolio: Clinical-Stage Stem Cell Therapies
Table 5.22 Pluristem Therapeutics: Recent Developments and Future Outlook
Table 5.23 Takeda Pharmaceutical: Company Profile
Table 5.24 Product Portfolio: Clinical-Stage Stem Cell Therapies
Table 5.25 Takeda Pharmaceutical: Recent Developments and Future Outlook
Table 5.26 TICEBA: Company Profile
Table 5.27 Product Portfolio: Clinical-Stage Stem Cell Therapies
Table 5.28 TICEBA: Recent Developments and Future Outlook
Table 6.1 Crohn’s Disease: Current Treatment Options
Table 6.2 Crohn’s Disease: Side Effects of Current Treatment Options
Table 6.3 Crohn’s Disease: Stem Cell Therapeutics Pipeline
Table 6.4 Ulcerative Colitis: Current Treatment Options
Table 6.5 Ulcerative Colitis: Side Effects of Current Treatment Options
Table 6.6 Ulcerative Colitis: Stem Cell Therapeutics Pipeline
Table 6.7 Peripheral Arterial Diseases: List of Marketed Drugs
Table 6.8 Critical Limb Ischemia: Stem Cell Therapeutics Pipeline
Table 6.9 Heart Failure: List of Marketed Drugs
Table 6.10 Heart Failure: Stem Cell Therapeutics Pipeline
Table 6.11 Heart Failure: List of Marketed Drugs
Table 6.12 Myocardial Infarction: List of Marketed Drugs
Table 6.13 Myocardial Infarction: Stem Cell Therapeutics Pipeline
Table 6.14 Acne Vulgaris: Current Treatment Options
Table 6.15 Acne Vulgaris: Side Effects of Current Treatment Options
Table 6.16 Acne Vulgaris: Stem Cell Therapeutics Pipeline
Table 6.17 Diabetes: Current Treatment Options
Table 6.18 Diabetes: Side Effects of Current Treatment Options
Table 6.19 Diabetes: Stem Cell Therapeutics Pipeline
Table 6.20 Non-Alcoholic Steatohepatitis: Stem Cell Therapeutics Pipeline
Table 6.21 Bladder Cancer: List of Marketed Targeted Therapeutics
Table 6.22 Breast Cancer: List of Marketed Targeted Therapeutics
Table 6.23 Colorectal Cancer: Side Effects of Current Treatments
Table 6.24 Kidney Cancer: List of Marketed Targeted Therapeutics
Table 6.25 Liver Cancer: List of Marketed Targeted Therapeutics
Table 6.26 Lung Cancer: List of Marketed Targeted Therapeutics
Table 6.27 Lung Cancer: Side Effects of Current Treatments
Table 6.28 Ovarian Cancer: List of Marketed Targeted Therapeutics
Table 6.29 Pancreatic Cancer: List of Marketed Targeted Therapeutics
Table 6.30 Pancreatic Cancer: Stem Cell Therapeutics Pipeline
Table 6.31 Alzheimer’s Disease: Current Treatment Options
Table 6.32 Alzheimer’s Disease: Stem Cell Therapeutics Pipeline
Table 6.33 Parkinson’s Disease: Current Treatment Options
Table 6.34 Parkinson’s Disease: Stem Cell Therapeutics Pipeline
Table 8.1 Grant Analysis: List of Most Attractive Grants
Table 10.1 Assessment Strategies for Different Manufacturing Processes
Table 10.2 Comparison of Key Factors for the Selection of CMOs: Harvey Ball Analysis
Table 10.3 List of Stem Cell Therapy CMOs (Industry Players): Information on Year of Establishment, Headquarters, Company Size and Type of Manufacturer
Table 10.4 List of Stem Cell Therapy CMOs (Industry Players): Information on Scale of Manufacturing
Table 10.5 List of Stem Cell Therapy CMOs (Industry Players): Information on Manufacturing Facility Location and Compliance Certifications
Table 10.6 List of Stem Cell Therapy CMOs (Industry Players): Information on Type of Services Offered
Table 10.7 List of Stem Cell Therapy CMOs (Industry Players): Information on Source and Origin of Stem Cell
Table 10.8 List of Stem Cell Therapy CMOs (Non-Industry Players): Information on Manufacturing Facility and cGMP Compliance
Table 10.9 List of Stem Cell Therapy CMOs (Non-Industry Players): Information on Scale of Manufacturing
Table 10.10 List of Stem Cell Therapy CMOs (Non-Industry Players): Information on Type of Services Offered
Table 10.11 List of Stem Cell Therapy CMOs (Non-Industry Players): Information on Source and Origin of Stem Cell
Table 12.1 CARTISTEM®: Therapy Overview
Table 12.2 HiQCell®: Therapy Overview
Table 12.3 Prochymal®: Therapy Overview
Table 12.4 Strimvelis®: Therapy Overview
Table 12.5 Strimvelis®: Presentations in Conferences After Product Approval
Table 12.6 Key Commercialization Strategies: Harvey Ball Analysis by Ease of Implementation,Value Addition and Current Adoption
Table 13.1 Stem Cell Therapies Market: List of Commercialized Therapies
Table 15.1 Seraxis: Company Snapshot
Table 15.2 Xcelthera: Company Snapshot
Table 15.3 Kadimastem: Company Snapshot
Table 15.4 Heartseed: Company Snapshot
Table 15.5 University of Rostock: Company Snapshot
Table 15.6 Bio Elpida: Company Snapshot
Table 15.7 Roslin Cell Therapies: Company Snapshot
Table 15.8 University of Minnesota: Company Snapshot
Table 15.9 Waisman Biomanufacturing: Company Snapshot
Table 15.10 YposKesi: Company Snapshot
Table 16.1 Historical Timeline: Analysis of Google Trends
Table 16.2 Geographical Activity: Analysis of Google Trends
Table 16.3 Stem Cell Therapies: Distribution by Phase of Development
Table 16.4 Stem Cell Therapies: Distribution by Source of Stem Cell
Table 16.5 Stem Cell Therapies: Distribution by Origin of Stem Cell
Table 16.6 Stem Cell Therapies: Distribution by Type of Stem Cell
Table 16.7 Stem Cell Therapies: Distribution by Lineage of Stem Cell
Table 16.8 Stem Cell Therapies: Distribution by Potency of Stem Cell
Table 16.9 Stem Cell Therapies: Distribution by Target Indication
Table 16.10 Stem Cell Therapies: Distribution by Therapeutic Area
Table 16.11 Stem Cell Therapies: Distribution by Route of Administration
Table 16.12 Stem Cell Therapy Developers: Distribution by Year of Establishment
Table 16.13 Stem Cell Therapy Developers: Distribution by Company Size
Table 16.14 Stem Cell Therapy Developers: Distribution by Location of Headquarters
Table 16.15 Stem Cell Therapy Developers: Distribution by Company Size and Location of Headquarters
Table 16.16 Leading Stem Cell Therapy Developers: Distribution by Number of Stem Cell Therapies
Table 16.17 Leading Stem Cell Therapy Developers: 4D Bubble Analysis based on Strength of Pipeline, Number of Therapies, Target Indication and Company Size
Table 16.18 Heptagon Representation: Distribution by Phase of Development and Key Therapeutic Area
Table 16.19 Grid Representation: Distribution by Phase of Development, Source of Stem Cell and Therapeutic Area
Table 16.20 Tree Map Representation: Distribution by Therapeutic Area and Size of the Company
Table 16.21 Relative Competition and Growth Opportunities Related to Stem Cell Therapies: Analytical Output
Table 16.22 Grant Analysis: Cumulative Trend by Year of Award, 2015-2019
Table 16.23 Grant Analysis: Cumulative Trend by Amount Awarded, 2015-2019 (USD Million)
Table 16.24 Grant Analysis: Distribution by Administering Institute Center
Table 16.25 Grant Analysis: Distribution by Funding Institute Center
Table 16.26 Grant Analysis: Distribution by Support Period
Table 16.27 Grant Analysis: Distribution by Funding Institute Center and Support Period
Table 16.28 Grant Analysis: Most Popular NIH Funding Categorizations
Table 16.29 Grant Analysis: Distribution by Funding Mechanism
Table 16.30 Grant Analysis: Distribution by Source of Stem Cell
Table 16.31 Grant Analysis: Distribution by Origin of Stem Cell
Table 16.32 Grant Analysis: Distribution by Type of Stem Cell
Table 16.33 Grant Analysis: Year-Wise Trend in Activity for Different Types of Stem Cells
Table 16.34 Grant Analysis: Year-Wise Trend in Amount Awarded for Different Types of Stem Cells (USD Million)
Table 16.35 Grant Analysis: Distribution by Lineage of Stem Cell
Table 16.36 Grant Analysis: Distribution by Potency of Stem Cell
Table 16.37 Grant Analysis: Analysis by Therapeutic Areas
Table 16.38 Grant Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
Table 16.39 Grant Analysis: Year-Wise Trend in Amount Awarded for Popular Therapeutic Areas (USD Million)
Table 16.40 Grant Analysis: Distribution by Type of Grant Application
Table 16.41 Grant Analysis: Popular NIH Departments
Table 16.42 Grant Analysis: Distribution by Study Section
Table 16.43 Grant Analysis: Types of Recipient Organizations
Table 16.44 Grant Analysis: Popular Recipient Organizations
Table 16.45 Grant Analysis: Distribution by Grant Mechanism
Table 16.46 Grant Analysis: Prominent Program Officers
Table 16.47 Grant Analysis: Regional Distribution of Recipient Organization
Table 16.48 Grant Analysis: Categorizations based on Weighted Attractiveness Scores
Table 16.49 Grant Analysis: Multivariate Grant Attractiveness Analysis
Table 16.50 Clinical Trial Analysis: Distribution by Trial Status
Table 16.51 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2019
Table 16.52 Clinical Trial Analysis: Distribution by Trial Phase
Table 16.53 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, 2011-2019
Table 16.54 Clinical Trial Analysis: Distribution by Study Design
Table 16.55 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Table 16.56 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 16.57 Clinical Trial Analysis: Leading Industry Players
Table 16.58 Clinical Trial Analysis: Analysis by Type of Stem Cell
Table 16.59 Clinical Trial Analysis: Cumulative Distribution by Type of Stem Cell and Trial Registration Year
Table 16.60 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 16.61 Clinical Trial Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
Table 16.62 Clinical Trial Analysis: Distribution by Patient Enrollment and Therapeutic Area
Table 16.63 Clinical Trial Analysis: Year-Wise Trend in Patient Enrollment (in thousands) for Popular Therapeutic Areas
Table 16.64 Clinical Trial Analysis: Distribution by Type of Stem Cell and Therapeutic Area
Table 16.65 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Table 16.66 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
Table 16.67 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient
Table 16.68 Stem Cell Therapy CMOs (Industry): Distribution by Year of Establishment
Table 16.69 Stem Cell Therapy CMOs (Industry): Distribution by Company Size
Table 16.70 Stem Cell Therapy CMOs (Industry): Distribution by Scale of Manufacturing
Table 16.71 Stem Cell Therapy CMOs (Industry): Distribution by Location of Headquarters
Table 16.72 Stem Cell Therapy CMOs (Industry): Distribution by Location of Manufacturing Facilities
Table 16.73 Stem Cell Therapy CMOs (Industry): Distribution by Types of Services Offered
Table 16.74 Stem Cell Therapy CMOs (Industry): Distribution by Source of Stem Cell
Table 16.75 Stem Cell Therapy CMOs (Industry): Distribution by Origin of Stem Cell
Table 16.76 Stem Cell Therapy CMOs (Non-Industry): Distribution by Year of Establishment
Table 16.77 Stem Cell Therapy CMOs (Non-Industry): Distribution by Scale of Manufacturing
Table 16.78 Stem Cell Therapy CMOs (Non-Industry): Distribution by Location of Headquarters
Table 16.79 Stem Cell Therapy CMOs (Non-Industry): Distribution by Location of Manufacturing Facilities
Table 16.80 Stem Cell Therapy CMOs (Non-Industry): Distribution by Types of Services Offered
Table 16.81 Stem Cell Therapy CMOs (Non-Industry): Distribution by Source of Stem Cell
Table 16.82 Stem Cell Therapy CMOs (Non-Industry): Distribution by Origin of Stem Cell
Table 16.83 Overall Stem Cell Therapies Market, 2020-2030 (USD Million)
Table 16.84 Stem Cell Therapies Market: Distribution by Source of Stem Cell, 2020 and 2030
Table 16.85 Stem Cell Therapies Market for Allogeneic Therapies, 2020-2030 (USD Million)
Table 16.86 Stem Cell Therapies Market for Autologous Therapies, 2020-2030 (USD Million)
Table 16.87 Stem Cell Therapies Market: Distribution by Origin of Stem Cell, 2020 and 2020
Table 16.88 Stem Cell Therapies Market for Adult Stem Cells, 2020-2030 (USD Million)
Table 16.89 Stem Cell Therapies Market for Embryonic Stem Cells, 2020-2030 (USD Million)
Table 16.90 Stem Cell Therapies Market: Distribution by Type of Stem Cell, 2020 and 2030
Table 16.91 Stem Cell Therapies Market for Hematopoietic Stem Cells, 2020-2030 (USD Million)
Table 16.92 Stem Cell Therapies Market for Mesenchymal Stem Cells, 2020-2030 (USD Million)
Table 16.93 Stem Cell Therapies Market for Progenitor Cells, 2020-2030 (USD Million)
Table 16.94 Stem Cell Therapies Market for Others, 2020-2030 (USD Million)
Table 16.95 Stem Cell Therapies Market: Distribution by Lineage of Stem Cell, 2020 and 2030
Table 16.96 Stem Cell Therapies Market for Adipose Tissue Derived Stem Cells, 2020-2030 (USD Million)
Table 16.97 Stem Cell Therapies Market for Bone Marrow Derived Stem Cells, 2020-2030 (USD Million)
Table 16.98 Stem Cell Therapies Market for Cord Blood Derived Stem Cells, 2020-2030 (USD Million)
Table 16.99 Stem Cell Therapies Market for Others, 2020-2030 (USD Million)
Table 16.100 Stem Cell Therapies Market: Distribution by Route of Administration, 2020 and 2030
Table 16.101 Stem Cell Therapies Market for Intraarticular Therapies, 2020-2030 (USD
Table 16.102 Stem Cell Therapies Market for Intracoronary Therapies, 2020-2030 (USD Million)
Table 16.103 Stem Cell Therapies Market for Intramuscular Therapies, 2020-2030 (USD Million)
Table 16.104 Stem Cell Therapies Market for Intramyocardial Therapies, 2020-2030 (USD Million)
Table 16.105 Stem Cell Therapies Market for Intrathecal Therapies, 2020-2030 (USD Million)
Table 16.106 Stem Cell Therapies Market for Intravenous Therapies, 2020-2030 (USD Million)
Table 16.107 Stem Cell Therapies Market for Surgical Implants, 2020-2030 (USD Million)
Table 16.108 Stem Cell Therapies Market for Others, 2020-2030 (USD Million)
Table 16.109 Stem Cell Therapies Market: Distribution by Therapeutic Area, 2020 and 2030
Table 16.110 Stem Cell Therapies Market for Autoimmune / Inflammatory Disorders, 2020-2030 (USD Million)
Table 16.111 Stem Cell Therapies Market for Cardiovascular Disorders, 2020-2030 (USD Million)
Table 16.112 Stem Cell Therapies Market for Metabolic Disorders, 2020-2030 (USD Million)
Table 16.113 Stem Cell Therapies Market for Musculoskeletal Disorders, 2020-2030 (USD Million)
Table 16.114 Stem Cell Therapies Market for Neurological Disorders, 2020-2030 (USD Million)
Table 16.115 Stem Cell Therapies Market for Oncological Disorders, 2020-2030 (USD Million)
Table 16.116 Stem Cell Therapies Market for Ophthalmic Disorders, 2020-2030 (USD Million)
Table 16.117 Stem Cell Therapies Market for Others, 2020-2030 (USD Million)
Table 16.118 Stem Cell Therapies Market: Distribution by End-Users, 2020 and 2030
Table 16.119 Stem Cell Therapies Market for Ambulatory Surgery Centers, 2020-2030 (USD Million)
Table 16.120 Stem Cell Therapies Market for Hospitals, 2020-2030 (USD Million)
Table 16.121 Stem Cell Therapies Market for Specialty Clinics, 2020-2030 (USD Million)
Table 16.122 Stem Cell Therapies Market: Distribution by Key Geographical Regions, 2020 and 2030
Table 16.123 Stem Cell Therapies Market in North America, 2020-2030 (USD Million)
Table 16.124 Stem Cell Therapies Market in Europe, 2020-2030 (USD Million)
Table 16.125 Stem Cell Therapies Market in Asia-Pacific and Rest of the World, 2020-2030 (USD Million)
The following companies and organizations have been mentioned in the report.
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES